Targeting Proteases in Cystic Fibrosis Lung Disease. Paradigms, Progress, and Potential

Am J Respir Crit Care Med. 2020 Jan 15;201(2):141-147. doi: 10.1164/rccm.201906-1190PP.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Chloride Channel Agonists / therapeutic use
  • Cysteine Proteases / metabolism*
  • Cysteine Proteinase Inhibitors / therapeutic use
  • Cystic Fibrosis / drug therapy
  • Cystic Fibrosis / metabolism*
  • Cystic Fibrosis Transmembrane Conductance Regulator / metabolism
  • Humans
  • Leukocyte Elastase / metabolism
  • Matrix Metalloproteinase Inhibitors / therapeutic use
  • Matrix Metalloproteinases / metabolism*
  • Molecular Targeted Therapy
  • Peptide Hydrolases / metabolism
  • Protease Inhibitors / therapeutic use
  • Serine Proteases / metabolism*
  • Serine Proteinase Inhibitors / therapeutic use

Substances

  • Chloride Channel Agonists
  • Cysteine Proteinase Inhibitors
  • Matrix Metalloproteinase Inhibitors
  • Protease Inhibitors
  • Serine Proteinase Inhibitors
  • Cystic Fibrosis Transmembrane Conductance Regulator
  • Cysteine Proteases
  • Peptide Hydrolases
  • Serine Proteases
  • Leukocyte Elastase
  • Matrix Metalloproteinases